Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maura Loprevite

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Histone deacetylation inhibitorsAndrea Ardizzoni, Maura Loprevite
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Farnesylated proteins as anticancer drug targets: from laboratory to the clinicPatrizia Russo, Maura Loprevite, Alfredo Cesario, et al.
European Journal of Pharmacology|August 2, 2003
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell linesAlessandra de Cupis, Claudia Semino, Paolo Pirani, et al.
Oncology Reports|January 14, 2004
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell linesMaura Loprevite, Roberto E Favoni, Alessandra De Cupis, et al.
Oncology Research|April 21, 2005
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell linesMaura Loprevite, Marcello Tiseo, Francesco Grossi, et al.
Anticancer Research|April 4, 2008
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancerMarcello Tiseo, Andrea Ardizzoni, Mara Argenide Cafferata, et al.
Clinical Chemistry|June 25, 2005
Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancerSonya Trombino, Monica Neri, Riccardo Puntoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancerMaura Loprevite, Marcello Tiseo, Maurizio Chiaramondia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancerMarcello Tiseo, Marzia Capelletti, Giuseppe De Palma, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Histone deacetylation inhibitorsAndrea Ardizzoni, Maura Loprevite
Current Medicinal Chemistry. Anti-Cancer Agents|March 23, 2004
Farnesylated proteins as anticancer drug targets: from laboratory to the clinicPatrizia Russo, Maura Loprevite, Alfredo Cesario, et al.
European Journal of Pharmacology|August 2, 2003
Enhanced effectiveness of last generation antiblastic compounds vs. cisplatin on malignant pleural mesothelioma cell linesAlessandra de Cupis, Claudia Semino, Paolo Pirani, et al.
Oncology Reports|January 14, 2004
In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell linesMaura Loprevite, Roberto E Favoni, Alessandra De Cupis, et al.
Oncology Research|April 21, 2005
In vitro study of CI-994, a histone deacetylase inhibitor, in non-small cell lung cancer cell linesMaura Loprevite, Marcello Tiseo, Francesco Grossi, et al.
Anticancer Research|April 4, 2008
Predictive and prognostic significance of neuron-specific enolase (NSE) in non-small cell lung cancerMarcello Tiseo, Andrea Ardizzoni, Mara Argenide Cafferata, et al.
Clinical Chemistry|June 25, 2005
Mutations in K-ras codon 12 detected in plasma DNA are not an indicator of disease in patients with non-small cell lung cancerSonya Trombino, Monica Neri, Riccardo Puntoni, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 3, 2007
Buccal mucosa cells as in vivo model to evaluate gefitinib activity in patients with advanced non small cell lung cancerMaura Loprevite, Marcello Tiseo, Maurizio Chiaramondia, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|October 2, 2008
Epidermal growth factor receptor intron-1 polymorphism predicts gefitinib outcome in advanced non-small cell lung cancerMarcello Tiseo, Marzia Capelletti, Giuseppe De Palma, et al.
Pageof 1